Sean Sadikot, MD
Pulmonary Disease · Hackensack, NJNPI 1003075110
Payments from drug & device makers
Across 346 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Boehringer Ingelheim$853
- Amgen$325
- Philips North America LLC$274
- Sanofi$214
- plus $2K from 32 others
What the payments were for
- Food & beverage$7,05898%
- Education$1112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 98 | $1,630 |
| AstraZeneca(2 entities) | 63 | $1,544 |
| Boehringer Ingelheim | 35 | $853 |
| Amgen | 14 | $325 |
| Philips North America LLC | 17 | $274 |
| Sanofi | 7 | $214 |
| Mylan Specialty L.p. | 12 | $213 |
| United Therapeutics Corporation | 9 | $172 |
| Merck | 9 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $148 |
| Pulmonx Corporation | 1 | $146 |
| Paratek Pharmaceuticals, Inc. | 5 | $139 |
| Regeneron Healthcare Solutions, Inc. | 8 | $137 |
| Viatris Specialty LLC | 6 | $119 |
| Shionogi Inc | 1 | $119 |
| Grifols USA, LLC | 5 | $88 |
| Verona Pharma, Inc. | 5 | $85 |
| AbbVie(2 entities) | 5 | $78 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $73 |
| Insmed, Inc. | 4 | $71 |
| Pfizer | 4 | $68 |
| Electromed, Inc. | 3 | $63 |
| Advanced Respiratory, Inc | 2 | $55 |
| Mallinckrodt Hospital Products Inc. | 4 | $52 |
| Mindray DS USA, Inc. | 1 | $47 |
| Baxter Healthcare | 2 | $47 |
| Inspire Medical Systems, Inc. | 1 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Medtronic | 1 | $26 |
| Bayer | 1 | $25 |
| Tactile Systems Technology Inc | 1 | $22 |
| Vivus LLC | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| UCB, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Optinose US, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$366
- FASENRA$235
- TEZSPIRE$232
- CHARTIS CATHETER$146
- ZEPHYR DELIVERY CATHETER$146
- ZEPHYR ENDOBRONCHIAL VALVE$146
- PULMONX CHARTIS TABLET CONSOLE$146
- DUPIXENT$125
- Fetroja$119
- OFEV$117
How this compares
$7,169 in reported general payments places this provider in the 70th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 249 | $269,579 |
| Dupixent PenDupilumab | 32 | $129,235 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 85 | $100,827 |
| Dupixent SyringeDupilumab | 15 | $58,417 |
| Breo ElliptaFluticasone/Vilanterol | 91 | $47,508 |
| Spiriva RespimatTiotropium Bromide | 52 | $35,187 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $22,089 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $10,770 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 63 | $9,931 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $8,113 |
| EliquisApixaban | 13 | $7,816 |
| Mycophenolate Mofetil | 14 | $7,086 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 214 | $6,660 |
| Atrovent HfaIpratropium Bromide | 11 | $5,540 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $5,130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,630 | $344,306378 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,544 | $108,940116 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $853 | $45,95663 claims |
| PfizerEliquis | $68 | $7,81613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Hackensack
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Emanuele SantomauroHackensack$420K
- Nadeem AliHackensack$133K
- Keith BrennerHackensack$42K
- John VillaHackensack$15K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.